Prior art

Patent US8926944B2 - Radiolabeled prostate specific membrane antigen inhibitors - Google Patents
Radiolabeled prostate specific membrane antigen inhibitors. US8926944B2. A method for delivering a therapeutic and/or diagnostic agent to a prostate specific membrane antigen (PSMA) expressing cell comprising contacting the PSMA expressing cell with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Formula (I) is:. This patent is cited by 79 patents. Filed Aug 5, 2011. Granted Jan 6, 2015.
https://patents.google.com/patent/US8926944B2/en
Patent US10398791B2 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer - Google Patents
Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer. US10398791B2. The invention relates to compounds of general formula (I) as PSMA inhibitors, which are suitable as radiopharmaceuticals for diagnosing and treating prostate cancer, and to pharmaceutical compositions comprising these compounds. This patent is cited by 33 patents. Filed Oct 18, 2013. Granted Sep 3, 2019.
https://patents.google.com/patent/US10398791B2/en
Patent US10471160B2 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer - Google Patents
Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer. US10471160B2. The invention relates to compounds of general formula (I) as PSMA inhibitors, which are suitable as radiopharmaceuticals for diagnosing and treating prostate cancer, and to pharmaceutical compositions comprising these compounds. This patent is cited by 26 patents. Filed Oct 18, 2013. Granted Nov 12, 2019.
https://patents.google.com/patent/US10471160B2/en
USPTO Patent Full Text and Image Database
https://patft.uspto.gov/netahtml/PTO/search-bool.html

Most Relevant Prior Art for US10980901

The following prior art references were cited in US patent 10980901:

1. US8926944B2

• Full Citation: US8926944B2, "Radiolabeled prostate specific membrane antigen inhibitors"
• Publication/Filing Date: Filed August 5, 2011; Granted January 6, 2015.
• Brief Description: This patent describes radiolabeled compounds designed to bind to Prostate Specific Membrane Antigen (PSMA) expressing cells for therapeutic and/or diagnostic purposes. It generally relates to methods for delivering therapeutic and/or diagnostic agents to PSMA-expressing cells using specific compound formulas.
• Potential Anticipated Claim(s): This patent broadly covers radiolabeled PSMA inhibitors. As such, it could potentially anticipate the general concept of using radiopharmaceuticals to target PSMA expressing cancers, as claimed in Claim 1 of US10980901, which outlines a method for treating PSMA expressing cancers by administering Ac-225-radiopharmaceuticals comprising Ac-225 chelated with a targeting compound. The specific formulas (A)-(E) in US10980901 would need to be critically compared against the compound formulas disclosed in US8926944B2 to determine direct anticipation of those specific structures.

2. US10398791B2

• Full Citation: US10398791B2, "Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer"
• Publication/Filing Date: Filed October 18, 2013; Granted September 3, 2019.
• Brief Description: This patent describes PSMA inhibitor compounds of a general formula (I) that are suitable as radiopharmaceuticals for diagnosing and treating prostate cancer, as well as pharmaceutical compositions containing these compounds.
• Potential Anticipated Claim(s): Similar to US8926944B2, this patent broadly covers labeled PSMA inhibitors for prostate cancer treatment. It could potentially anticipate the general method of treating PSMA expressing cancers with radiopharmaceuticals (e.g., Claim 1 of US10980901). A detailed comparison of the specific compound formulas and the use of Ac-225 in US10980901 against the disclosures in US10398791B2 would be necessary to ascertain specific anticipation of claims related to the particular Ac-225-radiopharmaceuticals or their specific dosages.

3. US10471160B2

• Full Citation: US10471160B2, "Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer"
• Publication/Filing Date: Filed October 18, 2013; Granted November 12, 2019.
• Brief Description: This patent describes PSMA inhibitor compounds of a general formula (I) that are suitable as radiopharmaceuticals for diagnosing and treating prostate cancer, and pharmaceutical compositions comprising these compounds.
• Potential Anticipated Claim(s): This patent is a continuation or related patent to US10398791B2 and shares a similar scope, broadly covering labeled PSMA inhibitors for prostate cancer diagnosis and treatment. Therefore, it has similar potential to anticipate the general aspects of Claim 1 of US10980901, particularly concerning the use of radiolabeled PSMA inhibitors for treating prostate cancer. The novelty of US10980901 lies in the specific use of Ac-225 and the defined dosage ranges, which would need to be specifically absent from the disclosures of US10471160B2 to avoid anticipation.